Laminar Pharma Announces first open-label Progression-Free Survival data for LAM561 in combination with standard of Care in First-Line Therapy for Newly Diagnosed Glioblastoma MGMT-methylated patients
PALMA DE MALLORCA, Spain, March 5, 2025 /PRNewswire/ -- Laminar Pharma, a leader…
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel, non-opioid intradiscal injection for the treatment of chronic Low Back Pain
Persica Pharmaceuticals announces positive Phase 1b clinical data for PP353, a novel,…
Allegro reports positive safety data for its injectable osteoarthritis treatment in three preclinical studies
Hydrocelin is potentially a first-in-class disease-modifying injectable treatment for osteoarthritisPivotal clinical trial…
Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025
March 01, 2025 12:45 ET | Source: Celldex Therapeutics, Inc. - Greatly…
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc.…
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month
STUDIO CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Myeloma Action Month…
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
TEZSPIRE significantly reduced nasal congestion, polyp size and nearly eliminated the need…
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
February 28, 2025 17:00 ET | Source: Keros Therapeutics, Inc. LEXINGTON, Mass.,…
4DMT Reports Full Year 2024 Financial Results, Operational Highlightsand Expected Upcoming Milestones
February 28, 2025 16:05 ET | Source: 4D Molecular Therapeutics, Inc. Presented…
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a…